尿激酶静脉溶栓治疗急性脑梗死的临床疗效研究

Study on the clinical efficacy of urokinase intravenous thrombolysis in patients with acute cerebral infarction

目的探讨尿激酶静脉溶栓治疗急性脑梗死的临床疗效。方法231例急性脑梗死患者作为研究对象,依据治疗方法不同将患者分为尿激酶溶栓组(120例)与常规治疗组(111例)。常规治疗组采用常规传统治疗,尿激酶溶栓组采用尿激酶静脉溶栓治疗。比较两组入院时、入院第3天、入院第7天美国国立卫生研究院卒中量表(NIHSS)评分及治疗效果。结果入院第3天、第7天,两组NIHSS评分均低于本组入院时,且尿激酶溶栓组入院第3天、第7天NIHSS评分分别为(8.21±0.75)、(4.69±0.65)分,均低于常规治疗组的(10.28±1.56)、(7.95±0.79)分,差异均有统计学意义(P<0.05)。尿激酶溶栓组治疗总有效率为88.33%,高于常规治疗组的74.77%,差异有统计学意义(P<0.05)。结论尿激酶静脉溶栓治疗能显著改善患者预后,提升急性脑梗死患者受损的神经功能,值得临床推广。

Objective To discuss the clinical efficacy of urokinase intravenous thrombolysis in patients with acute cerebral infarction.Methods A total of 231 patients with acute cerebral infarction were taken as the research subjects,and were divided into urokinase thrombolysis group(120 cases)and conventional treatment group(111 cases)according to different treatment methods.The conventional treatment group was treated with conventional traditional treatment,and the urokinase thrombolysis group was treated with urokinase intravenous thrombolysis.The National Institutes of Health stroke scale(NIHSS)scores and therapeutic effects were compared between the two groups on admission,on the 3rd day of admission,and on the 7th day of admission.Results On the 3rd and 7th day of admission,the NIHSS scores of the two groups were lower than those of this group on admission;the NIHSS scores of the urokinase thrombolysis group were(8.21±0.75)and(4.69±0.65)points on the 3rd and 7th days of admission,which were lower than(10.28±1.56)and(7.95±0.79)points of the conventional treatment group;all the differences were statistically significant(P<0.05).The total effective rate of treatment 88.33%in the urokinase thrombolysis group was higher than 74.77%in the conventional treatment group,and the difference was statistically significant(P<0.05).Conclusion Urokinase intravenous thrombolysis can effectively improves the prognosis of patients with acute cerebral infarction,enhance the patient's impaired neurological function,which is worthy of clinical promotion.